Supply Chain Challenges
Eli Lilly's GLP1 drugs, Zepbound and Mounjaro, are underperforming in sales, raising questions about the underlying issues. While the CEO attributes the revenue drop to supply chain constraints, analysts suggest that this could only explain a fraction of the decline. There’s a deeper problem at play, prompting speculation about the future of these medications in a competitive market.In this clip
From this podcast
The Prof G Pod with Scott Galloway
Prof G Markets: Meta’s AI Promise, Microsoft’s Disappointing Beat & Why Google Should Spin Youtube
Related Questions